Generic versions of weight-loss drugs are a bulky opportunity for Chinese and Indian drugmakers
The simultaneous patent expiry of Ozempic in China and India has seen generic makers jump in. Low cost production in high volumes affords them an export opportunity as well as this drug is adopted in large numbers not just to treat diabetes but for weight-loss around the world.
Post Comment